-
Something wrong with this record ?
Imiquimod nanocrystal-loaded dissolving microneedles prepared by DLP printing
E. Petrová, S. Chvíla, F. Štěpánek, J. Zbytovská, DA. Lamprou
Language English Country United States
Document type Journal Article
- MeSH
- Printing, Three-Dimensional * MeSH
- Administration, Cutaneous MeSH
- Imiquimod * chemistry administration & dosage MeSH
- Needles * MeSH
- Skin Absorption MeSH
- Skin metabolism MeSH
- Drug Delivery Systems instrumentation MeSH
- Microinjections instrumentation MeSH
- Nanoparticles * chemistry administration & dosage MeSH
- Polyethylene Glycols chemistry administration & dosage MeSH
- Povidone chemistry MeSH
- Solubility * MeSH
- Drug Liberation MeSH
- Animals MeSH
- Check Tag
- Animals MeSH
- Publication type
- Journal Article MeSH
The utilization of 3D printing- digital light processing (DLP) technique, for the direct fabrication of microneedles encounters the problem of drug solubility in printing resin, especially if it is predominantly composed of water. The possible solution how to ensure ideal belonging of drug and water-based printing resin is its pre-formulation in nanosuspension such as nanocrystals. This study investigates the feasibility of this approach on a resin containing nanocrystals of imiquimod (IMQ), an active used in (pre)cancerous skin conditions, well known for its problematic solubility and bioavailability. The resin blend of polyethylene glycol diacrylate and N-vinylpyrrolidone, and lithium phenyl-2,4,6-trimethylbenzoylphosphinate as a photoinitiator, was used, mixed with IMQ nanocrystals in water. The final microneedle-patches had 36 cylindrical microneedles arranged in a square grid, measuring approximately 600 μm in height and 500 μm in diameter. They contained 5wt% IMQ, which is equivalent to a commercially available cream. The homogeneity of IMQ distribution in the matrix was higher for nanocrystals compared to usual crystalline form. The release of IMQ from the patches was determined ex vivo in natural skin and revealed a 48% increase in efficacy for nanocrystal formulations compared to the crystalline form of IMQ.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25002953
- 003
- CZ-PrNML
- 005
- 20250206103955.0
- 007
- ta
- 008
- 250121s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s13346-024-01567-0 $2 doi
- 035 __
- $a (PubMed)38472727
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Petrová, Eliška $u School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, BT9 7BL, Belfast, UK $u Department of Organic Technology, University of Chemistry and Technology Prague, Faculty of Chemical Technology, Technická 5, 166 28, Prague 6, Czech Republic $1 https://orcid.org/0000000306918667
- 245 10
- $a Imiquimod nanocrystal-loaded dissolving microneedles prepared by DLP printing / $c E. Petrová, S. Chvíla, F. Štěpánek, J. Zbytovská, DA. Lamprou
- 520 9_
- $a The utilization of 3D printing- digital light processing (DLP) technique, for the direct fabrication of microneedles encounters the problem of drug solubility in printing resin, especially if it is predominantly composed of water. The possible solution how to ensure ideal belonging of drug and water-based printing resin is its pre-formulation in nanosuspension such as nanocrystals. This study investigates the feasibility of this approach on a resin containing nanocrystals of imiquimod (IMQ), an active used in (pre)cancerous skin conditions, well known for its problematic solubility and bioavailability. The resin blend of polyethylene glycol diacrylate and N-vinylpyrrolidone, and lithium phenyl-2,4,6-trimethylbenzoylphosphinate as a photoinitiator, was used, mixed with IMQ nanocrystals in water. The final microneedle-patches had 36 cylindrical microneedles arranged in a square grid, measuring approximately 600 μm in height and 500 μm in diameter. They contained 5wt% IMQ, which is equivalent to a commercially available cream. The homogeneity of IMQ distribution in the matrix was higher for nanocrystals compared to usual crystalline form. The release of IMQ from the patches was determined ex vivo in natural skin and revealed a 48% increase in efficacy for nanocrystal formulations compared to the crystalline form of IMQ.
- 650 12
- $a imichimod $x chemie $x aplikace a dávkování $7 D000077271
- 650 12
- $a jehly $7 D009339
- 650 12
- $a nanočástice $x chemie $x aplikace a dávkování $7 D053758
- 650 12
- $a 3D tisk $7 D066330
- 650 12
- $a rozpustnost $7 D012995
- 650 _2
- $a aplikace kožní $7 D000279
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a mikroinjekce $x přístrojové vybavení $7 D008845
- 650 _2
- $a uvolňování léčiv $7 D065546
- 650 _2
- $a kůže $x metabolismus $7 D012867
- 650 _2
- $a lékové transportní systémy $x přístrojové vybavení $7 D016503
- 650 _2
- $a polyethylenglykoly $x chemie $x aplikace a dávkování $7 D011092
- 650 _2
- $a kožní absorpce $7 D012869
- 650 _2
- $a povidon $x chemie $7 D011205
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Chvíla, Stanislav $u Faculty of Chemical Technology, Department of Organic Technology, University of Chemistry and Technology Prague, Technická 5, 166 28, Prague, Czech Republic $1 https://orcid.org/0000000329531756
- 700 1_
- $a Štěpánek, František $u Faculty of Chemical Technology, Department of Organic Technology, University of Chemistry and Technology Prague, Technická 5, 166 28, Prague, Czech Republic $1 https://orcid.org/0000000192884568 $7 mzk2012703367
- 700 1_
- $a Zbytovská, Jarmila $u Department of Organic Technology, University of Chemistry and Technology Prague, Faculty of Chemical Technology, Technická 5, 166 28, Prague 6, Czech Republic. jarmila.zbytovska@vscht.cz $1 https://orcid.org/0000000315418488 $7 xx0306236
- 700 1_
- $a Lamprou, Dimitrios A $u School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, BT9 7BL, Belfast, UK. d.lamprou@qub.ac.uk $1 https://orcid.org/0000000287401661
- 773 0_
- $w MED00197253 $t Drug delivery and translational research $x 2190-3948 $g Roč. 15, č. 1 (2025), s. 158-170
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38472727 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206103950 $b ABA008
- 999 __
- $a ok $b bmc $g 2263009 $s 1238960
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 15 $c 1 $d 158-170 $e 20240312 $i 2190-3948 $m Drug delivery and translational research $n Drug Deliv Transl Res $x MED00197253
- LZP __
- $a Pubmed-20250121